Tagged with Biotech,

UK With an appetite to take the next step in its rapid development, EUSA Pharma has already established itself as a leading rare-disease and oncology biotech company in just a short period of time. Currently active in both the UK and Europe, EUSA is set to further expand internationally, notably in…

India Bharat V. Daftary, chairman and MD of Bharat Serums & Vaccines (BSV), a biopharmaceutical company with R&D units in USA, Germany & India and with a presence in over 76 countries, provides insights into the biotech landscape in India and its expectations for the fertility and women’s health markets. He…

UK Keith Thompson, CEO of the Cell & Gene Therapy Catapult, one of a number of Catapult institutions in the UK designed to help commercialize innovative research, discusses strategy, funding, international collaboration and Brexit.     Most likely, the UK is the best environment for putting forward trials that are properly…

UK Terry O’Regan, VP and managing director at Biogen UK and Ireland, discusses the company’s longstanding commitment to the UK, market access issues, and why Biogen is staying the course with developing Alzheimer’s products at a time when many MNCs are winding down their neurology programs. How would you describe Biogen’s…

India India’s pharmaceutical sales and forecast from 2013 up to 2021. Between 2017 and 2021, the Indian pharma market is forecasted to grow by a CAGR of between nine and ten percent. The Indian biotechnology market grew by a CAGR of 20.33% between 2005 and 2015 and stood at USD 11.6…

India Satish Varma, managing director of Fermenta Biotech Ltd., one of the world’s largest and leading producers of Vitamin D3, provides insights into the indisputable benefits brought by the “Vitamin of the Century”, his approach to instill the best quality and regulatory standards in the company as well as his priorities…

Poland Artur Chabowski, president of Mabion, a pioneer Polish biotech player, discusses the historic partnership of their product, MabionCD20 with Mylan for the EU and Baltic states and the opportunities this opens up. Furthermore, he highlights the future potential of the biosimilar market and the company´s plans to design their own…

Lithuania Lithuania’s biotech sector has grown by between 20 and 25 percent over the last five years and accounts for over one percent of the entire country’s GDP. Key industry stakeholders are, however, split on whether Lithuania truly holds the potential to become a biotech hub that can stand alongside nations…

Canada At the company’s 40th anniversary, Biogen’s Canadian head Marina Vasiliou gives an insight into her priorities as new managing director, her approach to building relationships with all stakeholders in the healthcare system to ensure access to Biogen’s innovative treatments, and explains how the portfolio of the neuroscience leader is perfectly…

India Deloitte predicts that the global market for biosimilars will reach between USD 25 and 35 billion by 2020, driven by some key global biologic drugs facing loss of exclusivity in the next few years and an increasing global focus on improving healthcare access and the cost of care. Against this…

Poland Maciej Wieczorek, president of Celon Pharma, discusses the award-winning success of the 2016 IPO on the Warsaw stock exchange and the opportunities this has opened up, as well as investment strategy to assure the company’s impressive growth. Furthermore, he surveys the Polish R&D landscape and discusses the importance of a…

Canada Oliver Technow, president at BioVectra, highlights the company’s recent developments; amongst those a significant investment in a manufacturing site near Halifax. The resulting increase in manufacturing capacity by 40 percent will add to BioVectra’s position as the largest biotechnology company on Prince Edward Island, a historic location the CDMO is…